.Pharmacolibrary.Drugs.ATC.C.C01BB02

Information

Mexiletine is a class IB antiarrhythmic drug primarily used to treat ventricular arrhythmias, such as ventricular tachycardia. It is a sodium channel blocker structurally related to lidocaine. Mexiletine is administered orally and is currently approved for use in several countries.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers after oral administration.

References

1. Vozeh, S, et al., & Follath, F (1982). Population pharmacokinetic parameters in patients treated with oral mexiletine. European journal of clinical pharmacology 23(5) 445–451. DOI:10.1007/BF00605996 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7151850

2. Kobayashi, M, et al., & Ueno, K (2006). Effect of congestive heart failure on mexiletine pharmacokinetics in a Japanese population. Biological & pharmaceutical bulletin 29(11) 2267–2269. DOI:10.1248/bpb.29.2267 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17077526

3. Ueno, K, et al., & Shibakawa, M (2002). Evaluation of mexiletine clearance in a Japanese population. The Annals of pharmacotherapy 36(2) 241–245. DOI:10.1345/aph.10188 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11847941

Revisions

• 06/2025 initial generated model